tbuckley/cabot-search huggingface dataset:
Abstract 6947: Impact of Severe Anemia on Clinical Outcomes Following Left Ventricular Assist Device Implantation
Authors: Teruhiko Imamura, Stephanie Besser, Umar Siddiqi, Valluvan Jeevanandam
Journal: Circulation (2021)

Introduction: Patients with concomitant anemia and congestive heart failure have worse outcomes. The prevalence and clinical risk of significant anemia in patients receiving durable left ventricular assist device (LVAD) remain unknown. Methods: We retrospectively analyzed patients who underwent LVAD implantation between 2014 and 2018. The association between hemoglobin level at the time of index discharge and the one-year composite endpoint of heart failure readmissions or hemocompatibility-related adverse events was investigated. Results: A total of 167 patients (57 [48, 66] years old, 123 males) were included and stratified into a classification of severe anemia (hemoglobin &lt;9.7 g/dL, N = 99) or non-severe anemia (N = 68). The severe anemia group had a higher one-year incidence of the composite endpoint (56% versus 36%, p = 0.013) with a hazard ratio of 1.71 (95% confidence interval 1.07-2.75) after multivariate adjustment (Figure 1). Patients with severe anemia also experienced suboptimal LVAD unloading. Conclusions: Severe anemia was prevalent in LVAD patients and associated with a greater risk of heart failure and hemocompatibility-related adverse events. The optimal threshold for therapeutic intervention in response to anemia post-LVAD needs further investigation.
Abstract 12490: In a World Full of Talk, No One Wants to Discuss Death: An International Analysis of End-of-Life Discussions With Implantable Cardioverter Defibrillator Recipients
Authors: Jessica H Thompson, Misook L Chung, Jennifer Miller, Ingela Thylen, Chantal Ski, Thompson David, Donna Fitzsimons, Loreena Hill, Gabrielle McKee, Sharon A O'Donnell, Frances O'Brien, Mary Mooney, Kyoung S Lee, Seon Y Hwang, Debra K Moser
Journal: Circulation (2021)

Introduction: End-of-life (EOL) decision making in implantable cardioverter defibrillator (ICD) recipients is a difficult process that requires input from patients, families, and providers. International guidelines advise providers to discuss EOL scenarios with patients prior to ICD implantation, and throughout the life of the patient. Healthcare systems and culture differ across countries and may determine whether these conversations occur. The purpose of this study was to determine if country of origin affected whether an ICD recipient had engaged in a conversation with their provider or next-of-kin about EOL decisions related to the ICD. Methods: Participants (N = 682) from six countries—United States (US), Australia, Northern Ireland, Republic of Ireland, Sweden, and South Korea—completed demographic information, and an EOL questionnaire. Binomial logistic regression was used to examine if country of origin predicted whether patients had discussed EOL with an ICD with their providers or next of kin controlling for demographic (age and gender) and clinical (having a cardiac resynchronization therapy device, history of myocardial infarction and having received a shock from the ICD) variables. Results: Overall, 21% of participants had an EOL discussion with their provider, and 15% had an EOL discussion with their next-of-kin. Country of origin was a significant predictor of having had an EOL discussion with a provider (p=0.003) and next-of-kin (p=0.005). Significant differences were found between the US and Korea for discussions with providers (OR=0.265, p&lt;0.001) and next-of-kin (OR=0.301, p=0.003), and the US and Sweden for discussions with providers (OR=0.614, p=0.040) and next-of-kin (OR=0.537, p=0.021), with the US being the reference group. Having received a shock in the past was a significant predictor of having an EOL with providers (OR=2.275, p&lt;0.001) and next-of-kin (OR=1.692, p=0.019). Conclusions: End-of-life decision making is a complicated process, and a person’s cultural beliefs, along with healthcare system may play a role. These factors should be considered when creating interventions and policy to improve EOL discussions for patients with an ICD in order to improve quality of EOL care.
OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Subgroup Analysis By Prior Alkylator Exposed/Refractory Status
Authors: Pieter Sonneveld, Maria-Victoria Mateos, Pawel J. Robak, Fredrik H. Schjesvold, Roman Hajek, Paul G. Richardson, Johan Harmenberg, Marcus Thuresson, Catriona Byrne, Meletios-Athanasios Dimopoulos
Journal: Blood (2021)
SURG-07. ERAS IN NEURO-ONCOLOGY
Authors: mario moro, Viola Bartoletti, Enrico Giordan
Journal: Neuro-Oncology (2021)

Abstract BACKGROUND We performed a retrospective study assesses the efficacy and safety of a protocol for the enhanced clinical recovery of neuro-oncology patients undergoing surgery for supratentorial gliomas and metastasis. The protocol developed and applied to the Ca'Foncello Hospital in Treviso starts from the recommendations on the subject that the medical literature reported up to December 2018. Briefly, three main sections:1) preoperative functional status evaluation, preoperative oral carbohydrate loading; 2) minimally invasive surgery, scalp incision anesthesia, nonopioid analgesia; 3) early urinary-catheter removal, standing and feeding resumption within 3-4 hours from surgery. METHODS We collected and analyzed data on 28 patients operated on ERAS protocol and compared them to a control group (22 patients). The main clinical variables are: Charlson comorbidity index; times urinary-catether removal, adherence ambulation, taking food by mouth; hospital long of stay (LOS). We also collected studies from 2016 to 2020 describing data about ERAS and craniotomy and we pooled these into a meta-analysis. RESULTS Times urinary-catheter removal (3.1 vs 25 hours.), adherence to ambulation (4 vs 25 hours) and taking food by mouth (5.25 vs 23.72 hours) were significantly (p&amp;lt; 0.001) reduced in the ERAS group. Median hospital LOS was 2.85 days in the ERAS group and 4.77 days in the control group (p&amp;lt; 0.001). Our results overlapped those of the literature; the same trend was highlighted by our meta-analysis, with postoperative pain rates and hospital LOS significantly lower in ERAS patients (7.9 vs. 2.9 days, p &amp;lt; 0.001). A further important finding was that elderly patients (≥ 65 years) got the same outcomes as younger ones. CONCLUSIONS Our protocol for ERAS in neuro-oncology appears to have significant benefits over conventional management: it may improve patient outcomes, accelerate functional recovery, decrease length of stay, and enable patients to begin adjuvant chemotherapy and/or radiation in a more expeditious manner.
Hydrogels and Hydrogel Nanocomposites: Enhancing Healthcare through Human and Environmental Treatment
Authors: Angela M. Gutierrez, Erin Molly Frazar, Maria Victoria X. Klaus, Pranto Paul, J. Zach Hilt
Journal: Advanced Healthcare Materials (2021)

Humans are constantly exposed to exogenous chemicals throughout their life, which can lead to a multitude of negative health impacts. Advanced materials can play a key role in preventing or mitigating these impacts through a wide variety of applications. The tunable properties of hydrogels and hydrogel nanocomposites (e.g., swelling behavior, biocompatibility, stimuli responsiveness, functionality, etc.) have deemed them ideal platforms for removal of environmental contaminants, detoxification, and reduction of body burden from exogenous chemical exposures for prevention of disease initiation, and advanced treatment of chronic diseases, including cancer, diabetes, and cardiovascular disease. In this review, three main junctures where the use of hydrogel and hydrogel nanocomposite materials can intervene to positively impact human health are highlighted: 1) preventing exposures to environmental contaminants, 2) prophylactic treatments to prevent chronic disease initiation, and 3) treating chronic diseases after they have developed.
EPCO-18. A MESENCHYMAL CELL POPULATION MEDIATES RESISTANCE TO AURORA KINASE INHIBITORS IN GLIOBLASTOMA
Authors: Robert Suter, Vasileios Stathias, Anna Jermakowicz, Hari Pradhyumnan, Maurizio Affer, Florence Guglielmetti, Michael Ivan, Ricardo Komotar, Macarena de la Fuente, Jann Sarkaria, Stephan Schürer, Nagi Ayad
Journal: Neuro-Oncology (2021)

Abstract Glioblastoma (GBM) remains the most common adult brain cancer, with a dismal average patient survival of less than two years. No new treatments have been approved for GBM since the introduction of the alkylating agent temozolomide in 2005. Even then, temozolomide treatment only increases the average survival of GBM patients by a few months. Thus, novel therapeutic options are direly needed. The aurora kinases A and B are targetable and overexpressed in GBM, and their expression is highly correlated with patient survival outcomes. Our lab has found that small molecule aurora kinase inhibition reduces GBM tumor growth in vitro and in vivo, however, eventually tumors still grow. Computational analysis integrating compound transcriptional response signatures from the LINCS L1000 dataset with the single-cell RNA-sequencing data of patient GBM tumors resected at the University of Miami predicts that aurora inhibition targets a subset of cells present within any GBM tumor. Results of in vivo single-cell perturbation experiments with the aurora kinase inhibitor alisertib coincide with our predictions and reveal a cellular transcriptional phenotype resistant to aurora kinase inhibition, characterized by a mesenchymal expression program. We find that small molecules that are predicted to target different cell populations from alisertib, including this resistant mesenchymal population, synergize with alisertib to kill GBM cells. As a whole, we have identified the cellular population resistant to aurora kinase inhibition and have developed an analytical framework that identifies synergistic small molecule combinations by identifying compounds that target transcriptionally distinct cellular populations within GBM tumors.
Serum and ascites VEGF levels correlate with the clinical course of ovarian cancer patients
Authors: Anastasios Boutis, Charalambos Andreadis, Grammati Galaktidou, Despina Mouratidou, Alexandros H. Kortsaris
Journal: Cancer Research (2005)

4883  Background: Current laboratory and clinical data indicate a relationship between tumor neovascularization, metastatic potential and subsequent clinical course of cancer patients. Vascular endothelial growth factor (VEGF) stimulates tumor angiogenesis and has been proposed as a biological marker for the diagnosis, prognosis, evaluation of response to therapy and follow-up of ovarian cancer patients. Materials and methods: The concentration of VEGF was determined by enzyme-linked immunoadsorbent assay (ELISA) in the serum and ascetic fluid of 44 patients with epithelial ovarian cancer receiving cytotoxic chemotherapy. VEGF levels in the serum were measured consecutively before the initiation, during and/or after the completion of standard cytotoxic chemotherapy and ascetic fluid levels were determined once. The values have been correlated with the corresponding clinical status of the patients, initial disease stage as well as with standard tumor marker measurements (CA 125). Results: VEGF serum levels ranged between 34.6-1800 pg/ml and declined progressively during cytotoxic chemotherapy in patients with responding disease. The observed ascetic fluid levels of VEGF were higher than serum levels (61-4630 pg/ml) in 64% of the patients and correlated directly with the stage of the disease. Discussion: The results suggest that VEGF may be implicated in tumor progression and malignant ascites formation. Serum and ascetic fluid VEGF levels could serve as a useful marker for the monitoring of the clinical course of patients with epithelial ovarian cancer during chemotherapy. Further studies with larger patient samples are warranted to establish the value of this parameter.
NCOG-42. SYMPTOM ONSET TO TIME OF DIAGNOSIS IN PRIMARY CENTRAL NERVOUS SYSTEM TUMOR PATIENTS: A REVIEW OF FINDINGS FROM THE NOB-NHS
Authors: Matthew Lindsley, Elizabeth Vera, Alvina Acquaye, Nicole Briceno, Anna Choi, Alexa Christ, Ewa Grajkowska, Varna Jammula, Heather Leeper, Jason Levine, Jennifer Reyes, Kayla Roche, James Rogers, Michael Timmer, Lisa Boris, Eric Burton, Nicole Lollo, Marissa Panzer, Lily Polskin, Marta Penas-Prado, Valentina Pillai, Brett Theeler, Jing Wu, Mark Gilbert, Terri Armstrong
Journal: Neuro-Oncology (2021)

Abstract Prior reports suggest the low prevalence of primary central nervous system (PCNS) tumors and the healthcare setting where patients seek care can contribute to diagnostic delays, potentially affecting prognosis. This descriptive report highlights findings from patient-reported data at presentation collected from a sample of 623 PCNS tumor patients. Participants were White (88%), males (56%), median age at diagnosis 41 (2-79) with high grade (HG) (66%) brain tumors (BT) (89%). Among BT patients, 30% reported ≥ 3 concurrent symptoms at presentation including headaches (40%), seizures (30%), and memory problems or difficulty with balance/walking (20% each). Over half (57%) had symptoms for &amp;lt; 6 months before diagnosis and 60% presented to the Emergency Room. Sixty-five percent of HG BT patients had symptoms for &amp;lt; 6 months prior to diagnosis compared to low grade (LG) tumors (40%) and had surgery in &amp;lt; 1 month from presentation (68% vs 51%, p &amp;lt; 0.01). More HG BT patients presented with weakness in the arms/legs than LG BT (14% vs 8%). Among spine tumor (ST) patients, 45% reported ≥ 3 concurrent symptoms at presentation including back pain (65%), sensory changes (45%), and weakness (40%). Almost half (46%) were symptomatic for &amp;gt; 1 year before diagnosis, presented in an outpatient clinic (64%) with 41% having surgery &amp;lt; 1 month from presentation. Younger (40% vs 16%) and HG ST patients (56% vs 21%) more often reported symptoms for &amp;lt; 6 months before diagnosis. HG ST patients more often presented to Emergency Rooms (67% vs 25%) and had surgery &amp;lt; 1 month from presentation (60% vs 36%). Further analysis of symptom presentation and clinical course is ongoing. Tumor location, grade, patient age and healthcare setting were associated with the time from clinical presentation to diagnosis. Development of aids providing guidance on diagnostic evaluation/treatment to front-line healthcare providers is warranted.
Abstract 11973: Women Have Less Success of Thoracoscopic AF Ablation Than Men and Suffer More From Established Risk Factors
Authors: Robin Wesselink, Bente Mossink, Eva Meulendijks, Nicoline van den Berg, Jolien Neefs, Makiri Kawasaki, Femke Piersma, Rushd Al-Shama, Tim de Vries, Benedetta Fabrizi, Antoine Driessen, Wim Jan van Boven, Joris R de Groot
Journal: Circulation (2021)

Background: Women have more recurrent atrial fibrillation (AF) after AF ablation compared with men and are underrepresented in studies. What determines this worse outcome is incompletely understood. Objective: To explore the differential impact of established risk factors for AF recurrence in women and men. Methods: Consecutive patients (n=571) underwent thoracoscopic AF ablation. AF recurrence was defined as any atrial tachyarrhythmia &gt;30s on ECG or Holter, during 2 years of follow-up with exclusion of the first 90 days blanking period. Holters were performed at 3, 6, 9, 12, 15, 18, and 24 months. Predictors of AF recurrence were assessed and compared by sex using the Cox proportional hazards model. Risk ratios (RR) of predictors for AF recurrence were assessed by sex. Results: At thoracoscopic ablation, women were older (63±8 vs. 59±9 years, p&lt;0.001), had higher median [IQR] serum CRP (2.00 [0.90, 4.28] vs. 1.30 [0.65, 2.90] mg/ml p=0.006), but fewer cardiovascular risk factors (myocardial infarction (1.4% vs. 8.6%, p=0.03) and vascular disease (7.0% vs. 16.1%, p=0.01)). There was no difference in the prevalence of hypertension, heart failure, or diabetes mellitus. Freedom of AF recurrence until 2-year follow-up was 42.9% for women vs. 58.3% in men (p=0.002). The added risk for women was highest in patients with persistent AF (RR 1.4, p=0.001) (figure), aged &gt;67y (RR 1.43, p=0.04), and moderate left atrial dilatation (&gt;34 ml/m 2 ) (RR 1.32, p=0.01). Conclusion: Persistent AF, old age, and moderate left atrial enlargement more negatively affect AF freedom in women than in men. Meanwhile, women had similar or fewer cardiovascular risk factors compared to men, underscoring sex as an important contributor to AF recurrence.
Abstract 13135: Transfusion Requirements and Outcomes of Adult Patients With Congenital Heart Disease Undergoing Cardiovascular Surgery
Authors: Puja Dutta, Sirisha Emani, Meena Nathan, Sitaram Emani, Juan Ibla
Journal: Circulation (2021)

The number of adults with congenital heart disease (CHD) requiring cardiovascular (CV) surgery is increasing rapidly in the current era. We hypothesized that exposure to perioperative blood products is associated with poorer outcomes in adults. All adults (≥18 years old) undergoing CV surgery between 2015 and 2020 were reviewed retrospectively. Associations between transfusion (no products vs. any products) and outcomes were studied by univariate logistic regression and Wilcoxon rank sum tests. Multivariate cox/logistic regression was used to assess (a) postoperative ventilation time and length of stay, and (b) major complications, respectively. Of 323 patients, 147 (45%) received blood products during and/or after surgery. The median age was 27 (interquartile range [IQR]: 22-36) years, there were 181 (46%) males, and 16 (5%) patients had single ventricle anatomy. In the entire cohort, 110 (34%) were on preoperative anticoagulants: 39 (22%) received no products and 71 (48%) received products (OR: 3.28, 95% CI: [2.03,5.31], p&lt;0.0001), and 47 (15%) had prior sternotomies: 16 (9%) received no products and 31 (21%) received products (OR: 2.76, 95% CI: [1.44, 5.28], p=0.0022). Patients who received blood products had more complications overall (OR: 4.25, 95% CI: [2.10, 8.61], p&lt;0.0001) specifically, postoperative bleeding (OR: 7.54, 95% CI: [2.16, 26.28], p=0.0015) and cardiac arrest (OR: 8.75, 95% CI: [1.06, 71.94], p=0.04). Transfusion was associated with greater frequency of thrombosis (OR: 6.55, 95% CI: [1.86, 23.11], p=0.0035), longer ventilation time (HR: 3.05, 95% CI: [2.38, 3.91], p&lt;0.0001), and longer length of stay (HR: 2.65, 95% CI: [2.05, 3.42], p&lt;0.0001). In conclusion, adults who received perioperative blood products experienced more complications and worse in-hospital outcomes. Future research on optimizing blood product transfusion based on risk prediction models is needed to improve outcomes in adults with CHD undergoing CV surgery.
Prevalence of Medications That May Raise Blood Pressure Among Adults With Hypertension in the United States
Authors: John A. Vitarello, Clara J. Fitzgerald, Jennifer L. Cluett, Stephen P. Juraschek, Timothy S. Anderson
Journal: JAMA Internal Medicine (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
Pharmacological disruption of the MTDH–SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer
Authors: Minhong Shen, Heath A. Smith, Yong Wei, Yi-Zhou Jiang, Sheng Zhao, Nicole Wang, Michelle Rowicki, Yong Tang, Xiang Hang, Songyang Wu, Liling Wan, Zhi-Ming Shao, Yibin Kang
Journal: Nature Cancer (2021)
Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Authors: Mahesh Swaminathan, Amanda Przespolewski, Elizabeth A. Griffiths, James E. Thompson, Amro Elshoury, Wendy Walinski, Eunice S. Wang
Journal: Blood (2021)
Abstract P351: The Post-transcriptional Regulations Of Centrosomal <i>Plp</i> Mrna In <i>Drosophila</i>
Authors: Junnan Fang
Journal: Circulation Research (2021)

Centrosomes, functioning as microtubule organizing centers, are composed of a proteinaceous matrix of pericentriolar material (PCM) that surrounds a pair of centrioles. Drosophila Pericentrin (Pcnt)-like protein (PLP) is a key component of the centrosome that serves as a scaffold for PCM assembly. The disruption of plp in Drosophila results in embryonic lethality, while the deregulation of Pcnt in humans is associated with MOPD II and Trisomy 21.We recently found plp mRNA localizes to Drosophila embryonic centrosomes. While RNA is known to associate with centrosomes in diverse cell types, the elements required for plp mRNA localization to centrosomes remains completely unknown. Additionally, how plp translation is regulated to accommodate rapid cell divisions during early embryogenesis is unclear. RNA localization coupled with translational control is a conserved mechanism that functions in diverse cellular processes. Control of mRNA localization and translation is mediated by RNA-binding proteins (RBPs). We find PLP protein expression is specifically promoted by an RNA-binding protein, Orb, during embryogenesis; moreover, plp mRNA interacts with Orb. Importantly, we find overexpression of full-length PLP can rescue cell division defects and embryonic lethality caused by orb depletion. We aim to uncover the mechanisms underlying embryonic plp mRNA localization and function and how Orb regulates plp translation.
Abstract 10444: New Predictors and Long-Term Outcomes in ST-Elevation Myocardial Infarction with Cardiac Rupture After Primary Percutaneous Coronary Intervention
Authors: Hirofumi Kawamata, Kenji Yanishi, Keisuke Shoji, Yusuke Hori, Ayumu Fujioka, Satoshi Teramukai, Takeshi Nakamura, Satoaki Matoba
Journal: Circulation (2021)

Introduction: Cardiac rupture (CR) is a serious complication of acute myocardial infarction. Primary percutaneous coronary intervention (pPCI) reduces the incidence of CR. However, the risk factors and long-term outcomes in patients with CR after pPCI remain unclear. Aims: To investigate the clinical predictors and outcomes of CR after pPCI. Methods: This was a retrospective, case-control, multi-center study. A total of 2,444 consecutive patients with ST-elevation myocardial infarction (STEMI) undergoing pPCI from 2009 to 2015 were included; 33 patients had CR (1.4%): 19 were assigned as early-CR (≤72 h) and 14 as late-CR (&gt;72 h). The 132 controls (non-CR) were randomly selected by matching the 2,411 STEMI patients without CR at a 1:4 ratio. Results: Figure.1 showed that female, acute hyperglycemia, thrombocytopenia (platelet&lt;15х10 4 /μL), and incomplete revascularization (post-PCI thrombolysis in myocardial infarction [TIMI]&lt;3) were independent risk factors for CR (P&lt;0.05). Univariate logistic regression after adjusting age and sex showed that acute hyperglycemia and post-PCI TIMI&lt;3 were significantly associated with early-CR, whereas thrombocytopenia was strongly associated with late-CR. In-hospital mortality rate was significantly higher in the CR than the non-CR group (66.7% vs 6.8%, P&lt;0.0001). Emergency surgical repair exhibited a strong association with in-hospital death. Kaplan-Meier survival curve in Figure.2 showed no significant difference between surviving STEMI patients with CR and non-CR (Log-rank P=0.26). Conclusions: Acute hyperglycaemia and thrombocytopenia are new predict factors for early- and late-CR, respectively. The clinical risk factors of early- and late-CR in pPCI era may differ. Emergency surgical repair affects with in-hospital mortality, and surviving CR patients have a similar post-discharge survival rate compared with surviving non-CR patients.